---
title: "Cost-effectiveness of sulbactam‑durlobactam versus colistin for CRAB infections in US critical care"
id: "medrxiv-11-cost-effectiveness-of-sulbactam-durlobactam-compared-with-colistin-for-treating"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-11-cost-effectiveness-of-sulbactam-durlobactam-compared-with-colistin-for-treating"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.09.13.26362951v1?rss=1"
published_at: "2026-09-17T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Cost-effectiveness of sulbactam‑durlobactam versus colistin for CRAB infections in US critical care
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-11-cost-effectiveness-of-sulbactam-durlobactam-compared-with-colistin-for-treating
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.09.13.26362951v1?rss=1)
- **Published At:** 2026-09-17T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- A decision-analytic model compared **sulbactam-durlobactam** with **colistin** for treating carbapenem-resistant Acinetobacter baumannii (CRAB) infections in US critical care, using efficacy and safety data from the ATTACK trial. - The model included survival, clinical cure (complete vs incomplete), and the incidence and costs of acute kidney injury (AKI), which was more common with colistin. - Base-case expected per-patient costs were $57,887 for sulbactam-durlobactam and $55,157 for colistin. - Estimated survival was higher with sulbactam-durlobactam (0.66) than colistin (0.46), yielding 0.19 additional life saved per patient. - The incremental cost-effectiveness ratio (ICER) for sulbactam-durlobactam versus colistin was $14,097 per additional life saved in the base case. - Deterministic sensitivity analysis found the ICER most sensitive to the proportion of survivors with incomplete clinical cure, the costs of sulbactam-durlobactam and cefiderocol, and survival outcomes with sulbactam-durlobactam. - Scenario analyses produced ICERs ranging up to $69,758 per additional life saved and, under some assumptions, showed dominance favoring sulbactam-durlobactam. - Authors conclude that despite higher treatment costs, sulbactam-durlobactam has a favorable cost-effectiveness profile when AKI management costs are considered. - Study provenance: preprint on medRxiv; ATTACK trial provided clinical inputs; data are reported as contained within the manuscript. - Competing interests: three authors declared no conflicts; one author reported unrelated research funding from Pfizer.
## Clinical Analysis & Structured Key Points
Cost-Effectiveness of Sulbactam-durlobactam Compared with Colistin for Treating Carbapenem-Resistant Acinetobacter baumannii Infections in Critical Care Settings in the United States | medRxiv Skip to main content Cost-Effectiveness of Sulbactam-durlobactam Compared with Colistin for Treating Carbapenem-Resistant Acinetobacter baumannii Infections in Critical Care Settings in the United States View ORCID Profile Abiodun Ologunowa , View ORCID Profile Aisling Caffrey , View ORCID Profile Steven Cohen , View ORCID Profile Stephen Kogut doi: https://doi.org/10.64898/2026.09.13.26362951 Abiodun Ologunowa 1 Department of Pharmacy Practice and Clinical Research, College of Pharmacy, University of Rhode Island, Kingston, 02881, RI, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Abiodun Ologunowa For correspondence: aologunowa{at}uri.edu Aisling Caffrey 2 University of Rhode Island and Providence Veterans Affairs Healthcare System; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Aisling Caffrey Steven Cohen 3 Department of Public Health, College of Health Sciences, University of Rhode Island, Kingston, 02881, RI, USA. Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Steven Cohen Stephen Kogut 1 Department of Pharmacy Practice and Clinical Research, College of Pharmacy, University of Rhode Island, Kingston, 02881, RI, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Stephen Kogut Abstract Info/History Metrics Data/Code Preview PDF Abstract Objective: Carbapenem-resistant Acinetobacter baumannii (CRAB) infections present a significant public health challenge in the United States due to multidrug resistance, substantial added inpatient costs, and subsequently high mortality rates. Method: A decision-analytic model was developed to evaluate the cost-effectiveness of sulbactam-durlobactam compared to colistin for treating CRAB infections, using data from the Acinetobacter Treatment Trial Against Colistin (ATTACK) trial, in which patients received either sulbactam-durlobactam or colistin alongside imipenem-cilastatin. The model incorporated survival rates, clinical outcomes (complete or incomplete cure), and the incidence and costs of acute kidney injury, which is more frequent in colistin-treated patients. Deterministic sensitivity analysis and two scenario analyses were performed. Results: The base case analysis estimated an expected per-patient cost of $57,887 for sulbactam-durlobactam compared to $55,157 for colistin. Patients treated with sulbactam-durlobactam had higher survival than those treated with colistin (0.66 versus 0.46), corresponding to 0.19 additional life saved per patient. The incremental cost-effectiveness ratio (ICER) for sulbactam-durlobactam compared with colistin was $14,097 per additional life saved. The ICER was most sensitive to the proportion of survivors with incomplete clinical cure for both treatments, the costs of sulbactam-durlobactam and cefiderocol, and survival outcomes in patients treated with sulbactam-durlobactam. Scenario analyses showed that the cost-effectiveness of sulbactam-durlobactam was sensitive to clinical cure outcomes, with ICERs ranging from $69,758 per additional life saved to dominance favoring sulbactam-durlobactam under different assumptions. Conclusions: Although treatment costs were higher, sulbactam-durlobactam has a favorable cost-effectiveness profile as compared with colistin when accounting for the costs of managing acute kidney injury. Competing Interest Statement AO, SC, and SK have no conflict of interest to declare. ARC has received research funding from Pfizer for research unrelated to this study. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability All data produced in the present work are contained in the manuscript Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . Back to top Previous Posted September 17, 2026. Download PDF Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Cost-Effectiveness of Sulbactam-durlobactam Compared with Colistin for Treating Carbapenem-Resistant Acinetobacter baumannii Infections in Critical Care Settings in the United States Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Cost-Effectiveness of Sulbactam-durlobactam Compared with Colistin for Treating Carbapenem-Resistant Acinetobacter baumannii Infections in Critical Care Settings in the United States Abiodun Ologunowa , Aisling Caffrey , Steven Cohen , Stephen Kogut medRxiv 2026.09.13.26362951; doi: https://doi.org/10.64898/2026.09.13.26362951 Share This Article: Copy Citation Tools Cost-Effectiveness of Sulbactam-durlobactam Compared with Colistin for Treating Carbapenem-Resistant Acinetobacter baumannii Infections in Critical Care Settings in the United States Abiodun Ologunowa , Aisling Caffrey , Steven Cohen , Stephen Kogut medRxiv 2026.09.13.26362951; doi: https://doi.org/10.64898/2026.09.13.26362951 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Addiction Medicine (618) Allergy and Immunology (903) Anesthesia (334) Cardiovascular Medicine (4822) Dentistry and Oral Medicine (479) Dermatology (416) Emergency Medicine (650) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1632) Epidemiology (15962) Forensic Medicine (33) Gastroenterology (1203) Genetic and Genomic Medicine (7055) Geriatric Medicine (733) Health Economics (1066) Health Informatics (5054) Health Policy (1435) Health Systems and Quality Improvement (1773) Hematology (587) HIV/AIDS (1346) Infectious Diseases (except HIV/AIDS) (16298) Intensive Care and Critical Care Medicine (1174) Medical Education (670) Medical Ethics (155) Nephrology (725) Neurology (7286) Nursing (368) Nutrition (1082) Obstetrics and Gynecology (1243) Occupational and Environmental Health (1005) Oncology (3613) Ophthalmology (1054) Orthopedics (398) Otolaryngology (457) Pain Medicine (472) Palliative Medicine (139) Pathology (709) Pediatrics (1804) Pharmacology and Therapeutics (737) Primary Care Research (768) Psychiatry and Clinical Psychology (5910) Public and Global Health (9766) Radiology and Imaging (2429) Rehabilitation Medicine and Physical Therapy (1455) Respiratory Medicine (1249) Rheumatology (642) Sexual and Reproductive Health (772) Sports Medicine (578) Surgery (780) Toxicology (107) Transplantation (305) Urology (292)
## Related Clinical Research

- [Serum Magnesium and Risk of Spontaneous Bacterial Peritonitis and Sepsis in Hospitalized Cirrhosis](https://medichelpline.com/clinical-feed/frontiers-in-immunology-19-association-of-serum-magnesium-levels-with-the-risk-of-spontaneous-bacterial.md)
- [Iron-related Parameters and Sepsis-associated Acute Kidney Injury — Source Content Not Available](https://medichelpline.com/clinical-feed/frontiers-in-immunology-19-association-of-iron-related-parameters-with-the-development-of-sepsis.md)
- [Risk factors for 90-day RRT failure after cardiac surgery AKI treated with CRRT](https://medichelpline.com/clinical-feed/pubmed-42736125.md) (DOI: 10.3760/cma.j.cn112137-20260204-00393)
- [Biomarker Use for Acute Kidney Injury in Critically Ill Patients: Systematic Evidence Map and Prac](https://medichelpline.com/clinical-feed/pubmed-42725835.md) (DOI: 10.1097/CCM.0000000000007362)
- [BioBERT Clinical Text and Sparse Multi-Omics Components for Breast Cancer Survival Prediction: Cro](https://medichelpline.com/clinical-feed/medrxiv-2-biobert-derived-clinical-textrepresentations-and-sparse-principalcomponents-of.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.